ClinicalTrialsFinder
CompletedPhase 1ACTRN12605000782639

A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers

Sponsor

Epitan Limited

Enrollment

6 participants

Start Date

Jan 10, 2006

Study Type

Interventional

Conditions

Healthy male volunteersN/A

Summary

To determine how a new implant design of EPT1647 works in the body and to review any side effects that may occur.

Eligibility

Sex: MalesMin Age: 18 YearssMax Age: 45 Yearss

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying A phase I study to assess the pharmacokinetics of a single dose of a slow-release solid injection of EPT1647 in healthy male volunteers. You may be eligible if you are people aged 18 to 45, men. Participation typically involves medical assessments, possible treatment with the study intervention, and follow-up visits to track your health.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

EPT1647 is a derivative of MSH which has been shown to increase eumelanin levels in humans. This study will evaluate the safety and pharmacokinetic profiles of a new formulation of EPT1647 over 30 day

EPT1647 is a derivative of MSH which has been shown to increase eumelanin levels in humans. This study will evaluate the safety and pharmacokinetic profiles of a new formulation of EPT1647 over 30 days.

Locations(1)

SA, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000782639

Related Trials

The effect of Glycine Betaine on fasting and Post methionine load homocysteine concentrations in healthy volunteers.

ACTRN126050004346951 location